GENFIT (GNFT.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:GNFT - FR0004163111 - Common Stock
5.245 EUR
-0.02 (-0.38%)
Taking everything into account, GNFT scores 2 out of 10 in our fundamental rating. GNFT was compared to 81 industry peers in the Biotechnology industry. While GNFT seems to be doing ok healthwise, there are quite some concerns on its profitability. GNFT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
GNFT had negative earnings in the past year.
GNFT had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
In multiple years GNFT reported negative operating cash flow during the last 5 years.
1.2 Ratios
GNFT has a Return On Assets of -17.95%. This is comparable to the rest of the industry: GNFT outperforms 59.26% of its industry peers.
The Return On Equity of GNFT (-74.92%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.95% | ||
| ROE | -74.92% | ||
| ROIC | N/A |
ROA(3y)-8.89%
ROA(5y)-10.75%
ROE(3y)-21.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Profit Margin of GNFT has declined.
In the last couple of years the Operating Margin of GNFT has declined.
Looking at the Gross Margin, with a value of 95.42%, GNFT belongs to the top of the industry, outperforming 93.83% of the companies in the same industry.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
GNFT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% |
OM growth 3Y-50.61%
OM growth 5YN/A
PM growth 3Y-69.97%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
GNFT has about the same amout of shares outstanding than it did 1 year ago.
GNFT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GNFT has a worse debt to assets ratio.
2.2 Solvency
GNFT has an Altman-Z score of -1.21. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GNFT (-1.21) is comparable to the rest of the industry.
GNFT has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.09, GNFT is in the better half of the industry, outperforming 60.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.21 |
ROIC/WACCN/A
WACC7.28%
2.3 Liquidity
A Current Ratio of 3.69 indicates that GNFT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.69, GNFT is in the better half of the industry, outperforming 69.14% of the companies in the same industry.
GNFT has a Quick Ratio of 3.69. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
GNFT's Quick ratio of 3.69 is fine compared to the rest of the industry. GNFT outperforms 74.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.69 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
GNFT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -289.19%.
Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.84% on average per year.
The Revenue for GNFT has decreased by -45.94% in the past year. This is quite bad
GNFT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.84%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
3.2 Future
GNFT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.44% yearly.
GNFT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.86% yearly.
EPS Next Y-192.65%
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%
EPS Next 5Y-29.44%
Revenue Next Year-34.41%
Revenue Next 2Y-21.78%
Revenue Next 3Y-8%
Revenue Next 5Y-1.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GNFT's earnings are expected to decrease with -36.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:GNFT (1/2/2026, 5:29:46 PM)
5.245
-0.02 (-0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.73%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap262.27M
Revenue(TTM)45.41M
Net Income(TTM)-38.96M
Analysts90.77
Price Target8.79 (67.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.73%
PT rev (3m)-5.27%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-766.16%
EPS NY rev (3m)-180%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-28.49%
Revenue NY rev (3m)-30.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.78 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.95 | ||
| P/tB | 87.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.91
BVpS1.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.95% | ||
| ROE | -74.92% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% | ||
| FCFM | N/A |
ROA(3y)-8.89%
ROA(5y)-10.75%
ROE(3y)-21.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.61%
OM growth 5YN/A
PM growth 3Y-69.97%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 188.14% | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.69 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | -1.21 |
F-Score2
WACC7.28%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.84%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-192.65%
EPS Next 2Y-97.6%
EPS Next 3Y-36.76%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
Revenue Next Year-34.41%
Revenue Next 2Y-21.78%
Revenue Next 3Y-8%
Revenue Next 5Y-1.86%
EBIT growth 1Y-217.1%
EBIT growth 3Y-53.61%
EBIT growth 5YN/A
EBIT Next Year-89.66%
EBIT Next 3Y-36.71%
EBIT Next 5YN/A
FCF growth 1Y87.94%
FCF growth 3Y-46.73%
FCF growth 5YN/A
OCF growth 1Y94.06%
OCF growth 3Y-45.7%
OCF growth 5YN/A
GENFIT / GNFT.PA FAQ
What is the fundamental rating for GNFT stock?
ChartMill assigns a fundamental rating of 2 / 10 to GNFT.PA.
What is the valuation status for GNFT stock?
ChartMill assigns a valuation rating of 0 / 10 to GENFIT (GNFT.PA). This can be considered as Overvalued.
Can you provide the profitability details for GENFIT?
GENFIT (GNFT.PA) has a profitability rating of 2 / 10.
What is the expected EPS growth for GENFIT (GNFT.PA) stock?
The Earnings per Share (EPS) of GENFIT (GNFT.PA) is expected to decline by -192.65% in the next year.